According to Nymox Pharmaceutical's latest financial reports the company has a price-to-book ratio of -6.34.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2023-12-31 | -6.34 | -89.55% |
2022-12-31 | -60.7 | -72.13% |
2021-12-31 | -218 | -344.04% |
2020-12-31 | 89.3 | 96.45% |
2019-12-31 | 45.4 | 275.54% |
2018-12-31 | 12.1 | -108.43% |
2017-12-31 | -144 | -27.99% |
2016-12-31 | -199 | 289.1% |
2015-12-31 | -51.2 | 1392.35% |
2014-12-31 | -3.43 | -90.12% |
2013-12-31 | -34.7 | 12.29% |
2012-12-31 | -30.9 | -40.28% |
2011-12-31 | -51.8 | -35.52% |
2010-12-31 | -80.3 | -18.22% |
2009-12-31 | -98.2 | -369.1% |
2008-12-31 | 36.5 | -36% |
2007-12-31 | 57.0 | 8.19% |
2006-12-31 | 52.7 | 13.85% |
2005-12-31 | 46.3 | 30.03% |
2004-12-31 | 35.6 | 3.56% |
2003-12-31 | 34.4 | 25% |
2002-12-31 | 27.5 |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 5.20 | -182.03% | ๐บ๐ธ USA |
Pfizer PFE | 1.67 | -126.26% | ๐บ๐ธ USA |
Abbott Laboratories ABT | 4.78 | -175.29% | ๐บ๐ธ USA |
Eli Lilly LLY | 64.1 | -1,110.02% | ๐บ๐ธ USA |
Quest Diagnostics
DGX | 2.34 | -136.93% | ๐บ๐ธ USA |